Form 4: West Pharmaceutical Services SVP, Chief Technology Officer Silji Abraham Reports Stock Transactions

Silji Abraham, SVP and Chief Technology Officer of West Pharmaceutical Services, reports the acquisition and disposal of common stock and restricted stock units on October 29, 2024.

Summary

• On October 29, 2024, Silji Abraham, SVP, Chief Technology Officer of West Pharmaceutical Services, engaged in transactions involving the company's stock.
• Abraham acquired 458.024 shares of common stock through the vesting of restricted stock units.
• Simultaneously, Abraham disposed of 180.233 shares of common stock at a price of $318.41 per share.
• Following these transactions, Abraham directly owns 3,138.049 shares of West Pharmaceutical Services common stock.
• Additionally, 458.024 restricted stock units were released.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document simply reports stock transactions by an officer, which is a routine occurrence.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions, which can be informative for investors.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly increasing the number of outstanding shares, but the effect is likely negligible.

Key Dates